Oncology · AKT InhibitorRegulatory Approvalregulatorymid-term

AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 12:33:14 PM

Assessment confidence: 89% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's Approval Pending status for AstraZeneca's Capivasertib signals a significant step towards market entry, which could reshape competitive dynamics in the AKT inhibitor segment. Pharma strategy teams must prepare for potential shifts in market positioning as this product nears approval. Regulatory context from FDA (FDA AP — TRUQAP (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (27 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential competitive dynamics as Capivasertib approaches approval, including market positioning strategies. The strongest clinical anchor is Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Oncology · AKT Inhibitor, 7 regulatory and 5 competitive items passed relevance filtering for AstraZeneca.

Competitive Pressure

The most relevant competitive pressure comes from FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer (Humanexa Signals) — sponsor/company relevance (astrazeneca). Secondary pressure from FDA Approves PHESGO Supplement for Genentech's Combination Therapy. This AP status indicates that AstraZeneca is progressing towards potential market entry for Capivasertib, which may impact competitors in the AKT inhibitor space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — TRUQAP (SUPPL) (FDA). Entity match (astrazeneca); Regulatory pathway relevance (nda). The AP status indicates that AstraZeneca is on track for potential approval, which could lead to changes in regulatory compliance and market readiness for competing products.

Key Risks

Elevated medium regulatory exposure for AstraZeneca could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Capivasertib's entry could affect market share and revenue for existing AKT inhibitors, necessitating strategic adjustments from competitors.
Upside for AstraZeneca may improve if PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for AstraZeneca may improve if Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · HER2-positive Breast Cancer · Regulatory Approval · This approval enhances Genentech's position in the HER2-positive breast cancer market, potentially increasing market share against competitors.
Portfolio teams should prepare for potential competitive dynamics as Capivasertib approaches approval, including market positioning strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for final approval and any upcoming data releases that may influence market perception.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — TRUQAP (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRUQAP (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FENOFIBRIC ACID (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PADCEV (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
FDA Approves PHESGO Supplement for Genentech's Combination Therapy
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartishigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AstraZeneca
Capivasertib
competitors in oncology

Commercial impact

medium

Capivasertib's entry could affect market share and revenue for existing AKT inhibitors, necessitating strategic adjustments from competitors.

Regulatory impact

medium

The AP status indicates that AstraZeneca is on track for potential approval, which could lead to changes in regulatory compliance and market readiness for competing products.

What to watch

Monitor the timeline for final approval and any upcoming data releases that may influence market perception.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.